Apr. 2026
In April 2026, significant reduction of Grade 2 infusion related reactions (IRRs) was observed in all patients enrolled in the ongoing Qurgen Clinical trial with 48-hour continuous IV infusion using an infusion pump (from 85.2% using 90-minute IV infusion to 27.3% using 48-hour IV infusion with much mild Grade IRR). Only 2.1% Grade 3 AEs were observed (2 Grade 3 AEs in 95 patients, happened once for one individual patient per Grade 3 AE) and no Grade 4 and 5 AE has been observed in all 95-patients during Phase Ia trial. This new infusion regimen significantly enhanced the safety of SON-DP drug.